市场调查报告书
商品编码
1380247
全球癌症登记软体市场 2023-2030Global Cancer Registry Software Market 2023-2030 |
随着癌症盛行率较高和癌症登记软体的迅速采用,市场可能会成长。然而,患者资料的隐私和安全问题将限制市场成长。然而,政府越来越多地参与该软体的推广可能会为全球癌症登记软体市场的成长提供有利可图的机会。
全球癌症登记软体市场根据部署模型、资料库类型和最终用户产业进行细分。根据部署模型,市场分为基于云端的和本地的。根据资料库类型,市场分为商业资料库和公共资料库。根据最终用户行业,市场分为政府和第三方、私人付款人、医院和医疗实践等。
到 2022 年,医院和医疗实践在全球癌症登记软体市场中占据相当大的份额。医院中与癌症相关的手术数量不断增加,推动了该区域市场的高份额。患者一直依赖医院作为初级保健中心,这可能会推动该细分市场的成长。斯里兰卡是世界卫生组织东南亚区域的成员国之一,并获得国际癌症研究机构 (IARC) 以及位于孟买塔塔纪念中心的 IARC 区域中心的癌症登记技术支持, 印度。
对于癌症登记记录的资料管理,斯里兰卡国家癌症登记处 (SLNCR) 使用 IARC 开发的开源登记软体工具 CanReg5。 SLNCR 已收到来自全国 25 个中心的资料。区总医院、Avissawella、省总医院、巴杜拉、区总医院、奇洛、教学医院、卡卢塔拉姆、区总医院、综合医院、瓦武尼亚和Apeksha 医院(国家癌症研究所)是目前使用的斯里兰卡主要医院癌症登记软体。
Title: Global Cancer Registry Software Market Size, Share & Trends Analysis Report, By Deployment Model (On-Premise, Cloud-based), By Database Type (Commercial Database, Public Database), By End-User Industry (Government & Third Party, Private Payers, Hospital & Medical Practice, Others)Forecast Period (2023-2030).
Global cancer registry software market is anticipated to grow at a significant CAGR of 10.5% during the forecast period. The increasing prevalence of cancer, improving quality of care, and reducing healthcare costs along with recent developments by key players are driving the growth of the global cancer registry software market. According to the World Health Organization, Cancer was a leading cause of mortality worldwide, accounting for nearly 10 million mortalities in 2020, or nearly one in six casualties. The most common cancers include breast, lung, colon rectum, and prostate cancers. Additionally, according to estimates from the International Agency for Research on Cancer (IARC) updates from July 2021, by 2040, the global burden of cancers is expected to grow to 27.5 million new cancer cases and 16.3 million casualties globally. Such high burdens will increase the demand for cancer registry software as it would provide significant benefits in identifying the trend related to the prevalence and treatment of cancer.
With high cancer prevalence and rapid adoption of cancer registry software, the market is likely to grow. However, privacy and security concerns for patient data will be a restraint in the market growth. However, the growing involvement of the government in the promotion of this software is likely to offer lucrative opportunities for the growth of the global cancer registry software market.
The global cancer registry software market is segmented based on deployment model, database type, and end-user industry. Based on the deployment model, the market is segmented into cloud-based and on-premises. Based on database type, the market is segmented into commercial databases and public databases. Based on the end-user industry, the market is segmented into government & third party, private payers, hospital & medical practice, and others.
Hospital & medical practice held a considerable share of the global cancer registry software market in 2022. The rising number of cancer-related procedures in hospitals is contributing to the high share of the regional market. Patients have been relying on hospitals as primary care centers, which is likely to drive the growth of this market segment. Sri Lanka is one of the Member States of the World Health Organization's South-East Asia Region and receives technical support for cancer registration from the International Agency for Research on Cancer (IARC), and the IARC Regional Hub based at the Tata Memorial Centre in Mumbai, India.
For data management of cancer registry records, the Sri Lanka National Cancer Registry (SLNCR) uses the open-source registry software tool, CanReg5, as developed by IARC. The SLNCR has received data from 25 centers located across the country. District General Hospital, Avissawella, Provincial General Hospital, Badulla, District General Hospital, Chilaw, Teaching Hospital, Kalutaram, District General Hospital, General Hospital, Vavuniya, and Apeksha Hospital (National Cancer Institute) are the major Sri Lankan Hospitals that are currently using cancer registry software.
The global cancer registry software market is further segmented based on geography, including North America (the US and Canada), Europe (Italy, Spain, Germany, France, and others), Asia-Pacific (India, China, Japan, South Korea, and others), and the Rest of the World (the Middle East & Africa and Latin America).
Asia-Pacific to exhibit Highest Growth in the Global Cancer registry software Market
Regional growth is attributed to an increasing adoption of technology in the healthcare sector. Also increasing cases of cancer in the region is promoting the adoption of cancer registry software to identify the pattern of cancer for its better treatment. According to the Indian Council of Medical Research-National Cancer Registry Programme (ICMR-NCRP), the government informed Parliament the number of cancer cases in the country is projected to go up from $17.7 million in 2022 to $19.0 million in 2025. For instance, NITI Aayog, the public policy think tank of the Indian Government, aims to build an Imaging Biobank in association with the Department of Biotechnology, wherein it will create a database of cancer-related pathology and radiology images of more than 20,000 profiles of patients. Such images are creating a huge database for cancer registries; thereby driving the regional market growth.
The major companies serving the global cancer registry software market include: IBM Corp., Elekta, McKesson Corp., Siemens Healthineers, and Epic Systems among others. The market players are considerably contributing to the market growth by the adoption of various strategies, including mergers and acquisitions, partnerships, collaborations, funding, and new product launches, to stay competitive in the market. For instance, in September 2022, Electronic Registry Systems (ERS) Inc. and Nursenav Inc., an oncology navigation software, partnered to integrate their flagship software solutions, CRStar and CONNECT. This integration leverages cancer registry workflows and data collection to support services provided by oncology navigation. The integration between CRStar and CONNECT supports the creation of survivorship care plans by transmitting the diagnosis and treatment data directly into the patient's plan in CONNECT.